The purpose of the study is to see if the automatic system can improve outcomes for these infants, such as reducing the risk of complications like retinopathy of prematurity (a serious eye condition), chronic lung disease, and necrotizing enterocolitis (a severe intestinal disease). The study will also look at the overall survival and development of the infants up to 24 months after their expected due date. The trial will involve monitoring the infants closely to see if the automatic system provides better results than the manual method.

Throughout the study, infants will receive oxygen through standard infant ventilators, which are machines that help them breathe. The trial will last until the infants are discharged from the hospital, and their development will be assessed at 24 months. This research is important to potentially improve the care and outcomes for extremely preterm infants by ensuring they receive the right amount of oxygen in a safe and effective way.

The purpose of this study is to assess the long-term outcomes in children who previously received treatment for ROP in an earlier study. Researchers aim to evaluate the children’s visual acuity, which refers to the clarity or sharpness of vision, and to monitor the safety of the treatment over time. The study will also look at other aspects of eye health and development, such as the structure of the eye and neurodevelopmental outcomes, which involve the development of the brain and nervous system.

Participants in this study will be monitored over a period of time to gather information on their vision and overall health. The study will help determine how effective and safe the treatment is in the long run for children who have been affected by ROP. This information is crucial for understanding the potential benefits and risks of using Eylea in treating this condition.

The purpose of this study is to evaluate the long-term safety and visual outcomes of children who received this treatment in a previous study. Participants in this study will be monitored over several years to assess their vision and any potential side effects. The study will look at how well the children can see at different ages and whether they experience any eye-related or general health issues. It will also check for any structural changes in the eye, such as retinal detachment, which is when the retina pulls away from its normal position.

Throughout the study, researchers will also evaluate the children’s overall development using standardized tests. These tests will help determine if the treatment has any impact on their growth and learning abilities. The study aims to provide valuable information on the long-term effects of using Eylea for treating retinopathy of prematurity, helping to improve future care for children with this condition.

During the study, infants who are born before 28 weeks of pregnancy and have a birth weight below 1250 grams will be given either the medication or a placebo. The infants will be monitored over a period to see if the medication helps in preventing the progression of retinopathy of prematurity to a more severe stage. The study aims to find out if the infants can survive without developing severe retinopathy of prematurity, which might otherwise require treatments like laser surgery or injections into the eye.

The study will follow the infants for a certain period to observe the effects of the medication. The goal is to determine if propranolol hydrochloride can help in reducing the risk of severe eye problems in these very young infants, potentially improving their long-term eye health and vision outcomes.